Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01140516
Other study ID # ALPHA
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date July 2010
Est. completion date September 2024

Study information

Verified date October 2023
Source McMaster University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study focuses on the relationship between prophylaxis antibiotics and frequency of urinary tract infection in children diagnosed with antenatal hydronephrosis. Hydronephrosis is the most common fetal abnormality occurring in 1-5% of all pregnancies. Currently, with the widespread accessibility of antenatal ultrasound across cities in Ontario, the detection of hydronephrosis has become even more common. As a result, thousands of infants with hydronephrosis have been seen and managed by pediatricians, pediatric nephrologists, pediatric urologists, and family physicians. The investigators need to determine if antibiotic prophylaxis is effective in reducing the number of urinary tract infections in this population.


Description:

This study focuses on the relationship between prophylaxis antibiotics and frequency of urinary tract infection in children diagnosed with antenatal hydronephrosis. Hydronephrosis is the most common fetal abnormality occurring in 1-5% of all pregnancies. Currently, with the widespread accessibility of antenatal ultrasound across cities in Ontario, the detection of hydronephrosis has become even more common. As a result, thousands of infants with hydronephrosis have been seen and managed by pediatricians, pediatric nephrologists, pediatric urologists, and family physicians. The investigators need to determine if antibiotic prophylaxis is effective in reducing the number of urinary tract infections in this population.To determine whether CAP reduces the rate of UTI in infants with prenatal HN within the first 18 months of life. This is superiority, parallel, blinded, randomized, placebo-controlled trial in infants with prenatal HN testing the effect of CAP on febrile UTI rates over the first 18 months of life For clinical and safety purposes, data will be collected on symptoms and signs of febrile laboratory confirmed UTI (urinalysis, urine culture), compliance to treatment, adverse effects, and resistance to prophylactic antibiotics in case of positive urine cultures. As part of standard medical care, the patient and family are scheduled for renal-bladder ultrasounds and outpatient pediatric urology clinic visits at the local recruitment sites (i.e. McMaster Children's Hospital, The Hospital for Sick Children or, Children's Hospital of Eastern Ontario) during months as mentioned above at baseline, 3, 6, 9 and 12 months . During these clinic appointments, the research coordinator will follow up with patient and family regarding their progress in the study. The Research Coordinator will ask about any side effects from trial medication (nausea, vomiting, gastroenteritis, anaphylactic reactions) and ensure their questions or concerns are addressed. Data from patient's ultrasound assessment and renal scans will also be collected. In addition to clinic follow ups, patients and their families will be contacted monthly (excluding the months patient is scheduled for clinical follow up) by the Research Coordinator to further monitor patient's study progress. Families will be instructed to call the Research Coordinator at the first sign of febrile UTI (fever, loss of appetite, abdominal pain) and advised to seek medical assistance (bring their child to the Emergency Department at the local study institution). The baby will then have a dipstick taken to test for positive nitrites and leukocytes. If positive, patients are to have a urine sample via catheter specimen taken and if positive, be taken off study medication and be treated for febrile UTI according to standard medical practice. In this case the family and healthcare providers will not be unblinded to the participant's treatment allocation as this information is not required in order to treat the infant. In the event that parents are unable to bring their child to the local study institution, it is advised they obtain a dipstick and a catheter specimen from their local walk-in-clinic, Urgent Care Centre or family physician's office. If a catheter specimen is not available at these locations, a sterile bag may be used to determine outcome of urine sample. To ensure there is consistency between outside facilities, parents are given detailed instructions to obtain a dipstick and provide a photocopy of the results to the Research Coordinator for our records and potential adjudication. Letters will be faxed to the doctor that treated the child for the suspected UTI in order to obtain the associated reports.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 160
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 1 Month to 7 Months
Eligibility Inclusion Criteria: 1. Infants with AHN (one to seven months of age) confirmed postnatally with renal-bladder ultrasound and/or a dilated ureter = 7mm 2. SFU grade III and IV AHN (high grade hydronephrosis) 3. Patients without grades II to V VUR determined by voiding cystogram (includes UPJO-like and primary megaureter (hydroureteronephrosis) only); 4. Parent or legal guardian able to give free and informed consent Exclusion Criteria: 1. Infants with grades II to V VUR 2. Infants with posterior urethral valves or Prune-Belly syndrome 3. Duplication anomalies (ureteroceles, ectopic ureters) 4. Other conditions that may require chronic use of antibiotics 5. Previous renal failure 6. Allergy to trimethoprim 7. Co-enrollment in another intervention trial

Study Design


Intervention

Drug:
Trimethoprim
2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
Other:
Simple Syrup
2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.

Locations

Country Name City State
Canada McMaster Children's Hospital Hamitlon Ontario
Canada Sick Kids Hospital for Sick Children Toronto Ontario

Sponsors (4)

Lead Sponsor Collaborator
McMaster University Hamilton Health Sciences Corporation, McMaster Surgical Associates, The Physicians' Services Incorporated Foundation

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine whether antibiotics (ATB) prophylaxis prevents urinary tract infection (UTI) in infants with antenatal hydronephrosis (AHN). Determine the rate and frequence of UTI infection The outcome measures will be assessed at 12 months
See also
  Status Clinical Trial Phase
Completed NCT03235947 - Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients Phase 4
Withdrawn NCT01881165 - Cranberry on Urinary Tract Infections Phase 4
Terminated NCT02198833 - Efficacy of Micro-Patterned Foley Catheter to Reduce Catheter-Associated Urinary Tract Infection N/A
Completed NCT02357758 - Effects of Antibiotic Prophylaxis on Recurrent UTI in Children Phase 4
Completed NCT01687114 - Urinary Proanthocyanidin-A2 as a Biomarker of Compliance to Intake of Cranberry Products N/A
Completed NCT01391793 - Corticosteroids for Children With Febrile Urinary Tract Infections Phase 3
Completed NCT01219595 - Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women N/A
Completed NCT00365430 - SAFE or SORRY? Patient Safety Study of the Prevention of Adverse Patient Outcomes N/A
Recruiting NCT04502095 - Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy Phase 4
Completed NCT00976963 - Single Dose Monurol for Treatment of Acute Cystitis N/A
Recruiting NCT02568800 - Prolonged Infusion Cefepime and Nosocomial Infections Phase 3
Completed NCT02785445 - Healthy.io Method Comparison & User Performance Study N/A
Completed NCT02216253 - L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract to Prevent Postoperative Urinary Tract Infection. N/A
Completed NCT01478620 - Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI) Phase 3
Completed NCT01054690 - Silver Alloyed Urinary Catheters and Incidence of Catheter Acquired Urinary Tract Infections (UTI) N/A
Completed NCT00371631 - Colonizing Neurogenic Bladders With Benign Flora Phase 1
Terminated NCT03697993 - Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS) Phase 4
Terminated NCT01803919 - Efficacy Study of Antimicrobial Catheters to Avoid Urinary Infections in Spinal Cord Injured Patients N/A
Enrolling by invitation NCT01231737 - Efficacy of Two Prophylactic Schedules (Prulifloxacin Versus Phosphomycin) Phase 2
Completed NCT01763008 - A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections Phase 4